Co-Diagnostics

Co-Diagnostics EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Co-Diagnostics (CODX) as of Oct 16, 2026 is -126.44 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -62.63 % — a change of 101.89% (lower).

EBIT/Assets

-126.44 %

YoY

101.89%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Co-Diagnostics is 2025 -126.44 % . Operating Income to Assets Ratio (EBIT/Assets) of Co-Diagnostics was 2024 -62.63 % . It decreases by 101.89% lower compared to the previous year.

The Co-Diagnostics EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-395.11 USD
Jan 1, 2019
-274.86 USD
Jan 1, 2020
58.53 USD
Jan 1, 2021
28.78 USD
Jan 1, 2022
-21.92 USD
Jan 1, 2023
-44.80 USD
Jan 1, 2024
-62.63 USD
Jan 1, 2025
-126.44 USD
The Co-Diagnostics EBIT/Assets history
YEAREBIT/AssetsYoY
-126.44 %+101.89%
-62.63 %+39.78%
-44.80 %+104.40%
-21.92 %-176.15%
28.78 %-50.82%
58.53 %-121.29%
-274.86 %-30.43%
-395.11 %+177.06%
-142.61 %+9.48%
-130.26 %-75.45%
-530.55 %+33.28%
-398.07 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics Inc, listed on the NASDAQ with ticker CODX, is headquartered in Salt Lake City, Utah. The company develops, manufactures, and markets diagnostics technology, focusing on nucleic acid detection and analysis for diseases and pathogens. Its proprietary test design system and reagents support polymerase chain reaction diagnostics for conditions including tuberculosis, hepatitis, malaria, dengue, HIV, and Zika virus. The company employs 115 people and went public via IPO on July 12, 2017. It sells diagnostic equipment from other manufacturers as self-contained lab systems. Its website is http://codiagnostics.com/ Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Operating Income to Assets Ratio (EBIT/Assets) of Co-Diagnostics is -126.44 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Co-Diagnostics changed from -62.63 % to -126.44 %, representing a 101.89% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Co-Diagnostics

All Key Metrics — Co-Diagnostics